178 related articles for article (PubMed ID: 19107520)
1. Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro.
Darb-Esfahani S; Faggad A; Noske A; Weichert W; Buckendahl AC; Müller B; Budczies J; Röske A; Dietel M; Denkert C
J Cancer Res Clin Oncol; 2009 Jul; 135(7):933-41. PubMed ID: 19107520
[TBL] [Abstract][Full Text] [Related]
2. The expression of mammalian target of rapamycin in Ishikawa and HEC-1A cells.
Li X; Xiao L; Yang Y; Shen H; Zeng H; Wang Z
J Huazhong Univ Sci Technolog Med Sci; 2008 Jun; 28(3):340-2. PubMed ID: 18563337
[TBL] [Abstract][Full Text] [Related]
3. Mammalian target of rapamycin (mTOR) activity dependent phospho-protein expression in childhood acute lymphoblastic leukemia (ALL).
Nemes K; Sebestyén A; Márk A; Hajdu M; Kenessey I; Sticz T; Nagy E; Barna G; Váradi Z; Kovács G; Kopper L; Csóka M
PLoS One; 2013; 8(4):e59335. PubMed ID: 23573198
[TBL] [Abstract][Full Text] [Related]
4. EGFR- and AKT-mediated reduction in PTEN expression contributes to tyrphostin resistance and is reversed by mTOR inhibition in endometrial cancer cells.
Li T; Yang Y; Li X; Xu C; Meng L
Mol Cell Biochem; 2012 Feb; 361(1-2):19-29. PubMed ID: 21952748
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment.
Bae-Jump VL; Zhou C; Boggess JF; Whang YE; Barroilhet L; Gehrig PA
Gynecol Oncol; 2010 Dec; 119(3):579-85. PubMed ID: 20863555
[TBL] [Abstract][Full Text] [Related]
6. Targeting the mTOR/4E-BP pathway in endometrial cancer.
Korets SB; Czok S; Blank SV; Curtin JP; Schneider RJ
Clin Cancer Res; 2011 Dec; 17(24):7518-28. PubMed ID: 22142830
[TBL] [Abstract][Full Text] [Related]
7. Activation of Akt/mTOR pathway is associated with poor prognosis of nasopharyngeal carcinoma.
Wang W; Wen Q; Xu L; Xie G; Li J; Luo J; Chu S; Shi L; Huang D; Li J; Fan S
PLoS One; 2014; 9(8):e106098. PubMed ID: 25165983
[TBL] [Abstract][Full Text] [Related]
8. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of the mTOR pathway in intrahepatic cholangiocarcinoma.
Wang Z; Zheng T; Wu Q; Wang J; Wu C; Wang J
Neoplasma; 2012; 59(2):137-41. PubMed ID: 22248270
[TBL] [Abstract][Full Text] [Related]
10. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model.
Lang SA; Gaumann A; Koehl GE; Seidel U; Bataille F; Klein D; Ellis LM; Bolder U; Hofstaedter F; Schlitt HJ; Geissler EK; Stoeltzing O
Int J Cancer; 2007 Apr; 120(8):1803-10. PubMed ID: 17230506
[TBL] [Abstract][Full Text] [Related]
11. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma.
Lu KH; Wu W; Dave B; Slomovitz BM; Burke TW; Munsell MF; Broaddus RR; Walker CL
Clin Cancer Res; 2008 May; 14(9):2543-50. PubMed ID: 18451215
[TBL] [Abstract][Full Text] [Related]
12. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.
Xu G; Zhang W; Bertram P; Zheng XF; McLeod H
Int J Oncol; 2004 Apr; 24(4):893-900. PubMed ID: 15010827
[TBL] [Abstract][Full Text] [Related]
14. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer.
Meyer LA; Slomovitz BM; Djordjevic B; Westin SN; Iglesias DA; Munsell MF; Jiang Y; Schmandt R; Broaddus RR; Coleman RL; Galbincea JM; Lu KH
Int J Gynecol Cancer; 2014 May; 24(4):713-7. PubMed ID: 24651628
[TBL] [Abstract][Full Text] [Related]
15. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
[TBL] [Abstract][Full Text] [Related]
16. MiR-101 reduces cell proliferation and invasion and enhances apoptosis in endometrial cancer via regulating PI3K/Akt/mTOR.
Zhang S; Wang M; Li Q; Zhu P
Cancer Biomark; 2017 Dec; 21(1):179-186. PubMed ID: 29081412
[TBL] [Abstract][Full Text] [Related]
17. The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer.
Alabdullah ML; Ahmad DA; Moseley P; Madhusudan S; Chan S; Rakha E
J Obstet Gynaecol; 2019 May; 39(4):522-528. PubMed ID: 30712414
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells.
Zhou C; Gehrig PA; Whang YE; Boggess JF
Mol Cancer Ther; 2003 Aug; 2(8):789-95. PubMed ID: 12939469
[TBL] [Abstract][Full Text] [Related]
19. Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer.
No JH; Jeon YT; Park IA; Kim YB; Kim JW; Park NH; Kang SB; Han JY; Lim JM; Song YS
Gynecol Oncol; 2011 Apr; 121(1):8-12. PubMed ID: 21276607
[TBL] [Abstract][Full Text] [Related]
20. mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours.
Kasajima A; Pavel M; Darb-Esfahani S; Noske A; Stenzinger A; Sasano H; Dietel M; Denkert C; Röcken C; Wiedenmann B; Weichert W
Endocr Relat Cancer; 2011 Feb; 18(1):181-92. PubMed ID: 21159731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]